Target intelligence / Profile preview

Extra spindle pole bodies like 1 protein (separase) (ESPL1)

Target
ESPL1
Molecular classification
Enzyme, Cysteine protease, Cell cycle regulatory protein
01

Overview

Extra spindle pole bodies like 1 protein (separase), encoded by the ESPL1 gene, is a large cysteine protease essential for triggering the final separation of sister chromatids during anaphase of both mitosis and meiosis[1][2][3][5]. It acts by cleaving the α-kleisin subunit (such as RAD21 in mitosis or REC8 in meiosis) of the cohesin complex, dissolving cohesion between chromatids to ensure accurate chromosomal segregation[1][2][3]. Separase is tightly regulated by inhibitory proteins (notably securin) as well as phosphorylation cycles coordinated with the cell cycle to prevent premature chromatid separation[3][5]. Dysregulation—commonly overexpression or loss of inhibition—leads to chromosomal instability, aneuploidy, and has been repeatedly linked to tumorigenesis and poor prognosis in diverse cancers; thus, ESPL1 is both mechanistically central to proliferation and of translational interest as a therapeutic target and biomarker[4][5]. Besides its canonical role in mitosis, separase also participates in DNA damage repair, centrosome duplication, and spindle function, reflecting a range of cell cycle-related activities[5].

Other names
SeparinESP1KIAA0165SEPACaspase-like protein ESPL1Extra spindle poles-like 1 proteinCysteine protease ESPL1Extra spindle pole bodies homolog 1Separaseseparin
02

Mechanism of action

Proteolytic inhibition of separase blocks cohesin cleavage, arresting cells in metaphase and preventing chromatid separation[1][2][3][5]. Failed regulation can lead to chromosomal instability, a hallmark of several cancers[4].

03

Biological functions

Chromosome segregationSister chromatid separationCell cycle progression (mitosis and meiosis)DNA damage repairCentriole disengagementSpindle elongation
04

Disease associations

CancerAneuploidy-related diseasesCornelia de Lange syndromeChops syndrome
05

Safety considerations

Inhibition may disrupt essential chromosome segregation, leading to cytotoxicity and potentially non-specific toxicity in proliferative tissues.ESPL1 dysregulation linked to aneuploidy and chromosome instability, both of which promote oncogenesis[4]
06

Interacting drugs

No approved or clinical drugs directly targeting ESPL1/separase as of now; inhibitors have been proposed in the literature for research and preclinical use[2][4][5]
07

Biomarkers

Overexpression of ESPL1/separase is a proposed prognostic biomarker in several cancers (e.g., breast, endometrial, and potentially glioma)[4]

Beyond the preview

Go deeper on Extra spindle pole bodies like 1 protein (separase) (ESPL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Extra spindle pole bodies like 1 protein (separase) (ESPL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call